e-CAB 8 de setembre. Noves entrades

Noves Noticies i links del The National Prescribing Centre's Current Awareness Bulletin (eCAB) contains links to the latest health news, including clinical news, health and social care guidance, publications and policy.

National Prescribing Centre (NPC): http://www.npc.co.uk

· Dispensing with Repeats: A practical guide to repeat dispensing (2nd edition, 2008; 32-page pdf)

http://www.npci.org.uk/medicines_management/patients/repeatdisp/resources/dwr_for_web.pdf

NPCi Blog http://www.npci.org.uk/blog/
· MeReC Rapid Review: Cholesterol measurements in the first few years of statin treatment may mislead (updated) http://www.npci.org.uk/blog/?p=185

BBC Health News: http://news.bbc.co.uk/1/hi/health/default.stm
· Weekly diabetes jab hopes raised http://news.bbc.co.uk/1/hi/health/7603676.stm

BMJ: http://bmj.com/
· News: People in deprived areas of England are less likely to survive cancer http://www.bmj.com/cgi/content/full/337/sep08_1/a1598?q=rss_home

· Clinical review: Management of sickle cell disease http://www.bmj.com/cgi/content/full/337/sep08_1/a1397?q=rss_home
InfoPOEMs: http://www.essentialevidenceplus.com/

· Sildenafil may improve antidepressant-induced sexual dysfunction in women http://www.essentialevidenceplus.com/infopoems/dailyInfoPOEM.cfm?view=122735

National electronic Library for Medicines (NeLM): http://www.nelm.nhs.uk

· RCT: Effect of the frequency of self-monitoring blood glucose in patients with type 2 diabetes treated with oral antidiabetics http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/RCT-Effect-of-the-frequency-of-self-monitoring-blood-glucose-in-patients-with-type-2-diabetes-treated-with-oral-antidiabetics/
·

DH issues draft document for comment: pandemic influenza - surge capacity and prioritisation in health services http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/DH-issues-draft-document-for-comment-pandemic-influenza---surge-capacity-and-prioritisation-in-health-services/
·

Payment by Results for kidney dialysis project group: interim report, June 2008 http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Payment-by-Results-for-kidney-dialysis-project-group-interim-report-June-2008/

· Editorial: identifying safety signals in clinical trials around the link between ezetimibe and cancer http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Editorial-identifying-safety-signals-in-clinical-trials-around-the-link-between-ezetimibe-and-cancer/

· Anticonvulsants and possible suicidality – communicating risks when there’s not much data http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Anticonvulsants-and-possible-suicidality--communicating-risks-when-theres-not-much-data/

· King's Fund: Widespread variations remain in local NHS spending http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Kings-Fund-Widespread-variations-remain-in-local-NHS-spending/

· ‘Behind the Headlines’ assessment of reports on new research finding no link between MMR vaccination and autism http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Behind-the-Headlines-assessment-of-reports-on-new-research-finding-no-link-between-MMR-vaccination-and-autism-/

· US-based economic evaluation of sunitinib maleate for the first-line treatment of metastatic renal cell carcinoma http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/US-based-economic-evaluation-of-sunitinib-maleate-for-the-first-line-treatment-of-metastatic-renal-cell-carcinoma/

· Anatomy of a “seeding trial” – a clinical trial as drug marketing http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Anatomy-of-a-seeding-trial--a-clinical-trial-as-drug-marketing/

· Horizon scanning: exenatide once-weekly non-inferior to twice daily in type 2 diabetes? http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Horizon-scanning-exenatide-once-weekly-non-inferior-to-twice-daily-in-type-2-diabetes-/

· Systematic review: studies reporting positive and statistically significant outcomes more likely to be published? http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Systematic-review-studies-reporting-positive-and-statistically-significant-outcomes-more-likely-to-be-published--/

· Horizon scanning: experimental osteoporosis drug lasofoxifene (Fablyn®) linked to higher number of deaths versus placebo http://www.nelm.nhs.uk/en/NeLM-Area/News/2008---September/08/Horizon-scanning-experimental-osteoporosis-drug-lasofoxifene-Fablyn-linked-to-higher-number-of-deaths-versus-placebo/

· Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Disease-Focused-Reviews/Acceleration-and-augmentation-of-antidepressants-with-lithium-for-depressive-disorders-two-meta-analyses-of-randomized-placebo-controlled-trials/

· Utility of monitoring mycophenolic acid in solid organ transplant patients http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/Utility-of-monitoring-mycophenolic-acid-in-solid-organ-transplant-patients/

National Library for Health (NLH): http://www.library.nhs.uk
Behind the Headlines:
· Height and prostate cancer http://www.nhs.uk/news/2008/09September/Pages/Heightandprostatecancer.aspx
· Research shows no MMR–autism link http://www.nhs.uk/news/2008/09September/Pages/ResearchshowsnoMMRautismlink.aspx

NHS Confederation: http://www.nhsconfed.org/
· NHS Confederation comments on patient choice survey findings http://www.nhsconfed.org/issues/mediacentre-listing.cfm/pressrelease/819

NHS Networks: http://www.networks.nhs.uk/
· NHS Next Stage Review, Our vision for primary and community care newsletter http://www.networks.nhs.uk/news.php?nid=2380

PJ Online: http://www.pjonline.com
· Two stroke treatments are equivalent http://www.pjonline.com/news/two_stroke_treatments_are_equivalent
· Reduction in heart rate could reduce coronary artery disease morbidity http://www.pjonline.com/news/reduction_in_heart_rate_could_reduce_coronary_artery_disease_morbidity

Scottish Medicines Consortium (SMC): http://www.scottishmedicines.org/
Accepted for use within NHS Scotland:

· Ropinorole prolonged release (Requip XL) for the treatment of idiopathic Parkinson's Disease. It is accepted for use in patients already taking ropinirole immediate release tablets and in whom adequate symptomatic control has been established.
Accepted for restricted use within NHS Scotland:

· Pemetrexed (Alimta) as monotherapy for second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. It is restricted to use in patients with good performance status who would otherwise be eligible for treatment with docetaxel.

· Rituximab (MabThera) for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy. Rituximab is restricted to use only by haematologists or oncologists who have expertise in treating lymphoma. It should be administered in a healthcare environment where full resuscitation facilities are available.

· Micafungin (Mycamine) for the treatment of invasive candidiasis. It is restricted to use in the treatment of invasive candidiasis in adults, elderly, and children (including neonates).

· Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate. It is restricted to use in patients with previously untreated B-CLL, with the cytogenetic abnormality 17p-deletion.
Not recommended for use within NHS Scotland:

· Aripiprazole (Abilify) for the treatment of moderate to severe manic episodes in bipolar I disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.
TNSMI Health News (formerly Presswatch Health News) http://www.presswatch.com/health/

Headlines: http://www.presswatch.com/health/?d=2008-09-08#1
· 10 ways to cut the costs of being sick
· 58 in uniforms
· Study links mobile phones to tumours
· Weekly jab offers hope for diabetes sufferers
· Prince's alternative therapist sued by double amputee
· NHS and Health Sector News

The provision of a link to an item on eCAB shall not be taken as an endorsement of any kind. Please read the eCAB Terms and Conditions at http://www.npc.co.uk/pdf/terms_and_conditions/npc_tandcs.pdf.
For an explanation of the eCAB selection criteria, please see http://www.npc.co.uk/pdf/eCAB_scope.pdf.
For a copy of the NPC privacy policy please see http://www.npc.co.uk/pdf/terms_and_conditions/npc_privacy_policy.pdf.
To unsubscribe, please send a message to john.rowan@npc.nhs.uk with the subject heading 'Unsubscribe Daily eCAB '.